etrasimod (APD334) - Arena
Etrasimod: "Patients who received etrasimod 2 mg exhibited significant decreases in both fecal calprotectin and C-reactive protein versus placebo"; Ulcerative colitis (Arena) - May 22, 2019 - DDW 2019 
P2 data
https://www.arenapharm.com/publications/
 
May 22, 2019
 
 
3fe9ee20-7733-4340-b4ad-2834bf32a26c.jpg

4638ff08-0954-4266-a7fb-6af959e55f9d.jpg

631b2fd2-cf2c-48f1-983c-5fc6868e711a.jpg